A former Guernsey resident and creator of a controversial 'wonder drug' will stand trial for risking patient safety to pocket millions from the sale of outlawed medicines.
David Noakes, 64, is the CEO and beneficial owner of Immuno Biotech Ltd.
He appeared at Southwark Crown Court today alongside associate Brian Hall, biochemist Emma Ward and ex-wife and distribution firm director Loraine Noakes.
He is said to have used the firm to actively promote products containing GcMAF, made using human blood, by holding it out as a cure for a number of illnesses and conditions including cancer, multiple sclerosis, HIV and autism.
But products containing GcMAF are thought to cause a significant health risk.
Noakes also denied money laundering in relation to £7 million paid into Immuno's Guernsey bank accounts and a further £2 million he raked in personally from sales of GcMAF.
Their trial, expected to last up to six weeks, will take place at Southwark Crown Court on 5 November 2018.